{"id":"parg","name":"PARG","symbol":"PARG","route":"/targets/parg/","asOf":"2026-11-03","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8605","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000227345","uniprot":"https://www.uniprot.org/uniprotkb/Q86W56/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q86W56","open-targets":"https://platform.opentargets.org/target/ENSG00000227345","civic":"https://civicdb.org/genes/8505/summary","oncokb":"https://www.oncokb.org/gene/PARG","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PARG","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PARG","depmap":"https://depmap.org/portal/gene/PARG?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000227345-PARG","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/8505","omim":"https://www.omim.org/entry/603501"}],"products":[{"id":"dat-2645","name":"DAT-2645","status":"phase-2","modality":"Small molecule (oral tablet)","route":"/drugs/dat-2645/"},{"id":"etx-19477","name":"ETX-19477","status":"phase-1","modality":"Small molecule (oral)","route":"/drugs/etx-19477/"}],"trials":[{"id":"nct07652073","name":"A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer","nct":"NCT07652073","phase":"2","status":"planned"},{"id":"nct06614751","name":"A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway","nct":"NCT06614751","phase":"1","status":"planned"}],"pathways":[],"companies":["858-therapeutics","danatlas-pharmaceuticals"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}